Gilead Sciences secures $1.5 billion licensing deal for cancer candidate GH31
Gilead Sciences has agreed a global licensing deal worth up to $1.5 billion with China's Genhouse Bio for its synthetic lethal cancer candidate GH31, a MAT2A inhibitor with IND clearance in the USA and China.
US biotech Gilead Sciences (Nasdaq: GILD) has agreed a global licensing deal worth up to $1.5 billion with China's Genhouse Bio for its synthetic lethal cancer candidate GH31. Gilead will pay $80 million upfront for exclusive worldwide development and commercialization rights to the MAT2A inhibitor.
Genhouse is eligible for up to $1.45 billion in development, regulatory and commercial milestones, plus tiered double-digit royalties on net sales.
GH31 is a biomarker-driven synthetic lethal therapy targeting the rate-limiting enzyme MAT2A, with potential across multiple tumor types. The candidate has secured IND clearance in both the USA and China, enabling immediate clinical development.
Gilead will assume full responsibility for global development, regulatory filings and commercialization.